Home / Media / COVID-19 | Updates

COVID-19 | Updates

Latest news on DiaSorin's response to COVID-19 outbreak

DiaSorin's response to COVID-19 continues through research projects that have been developed at the Saluggia and Gerenzano Centers in Italy, with the valuable assistance of two major Italian Hospitals in Rome and Pavia.

In February and March, from the novel coronavirus outbreak, DiaSorin has promptly devised and developed a rapid and accurate molecular diagnostic test on our LIAISON MDX platform intended to detect all the currently known variants of the COVID-19.  The test enables sample-to-answer results within less than 60 minutes compared to the 5-7 hours currently necessary to report patient results.

On April 7, we announced the development of a new IgG CLIA test to identify antibodies against the SARS-CoV-2. The test will allow to detect antibodies directed against the virus in patients’ sera samples, identifying subjects who have developed an immune response to the virus, offering a valuable tool for epidemiologic assessment of populations.

The blood sample analysis will help identify those who have developed a response to the virus in about an hour.

Contact numbers: 

  • From Italy 800016268
  • From other countries +39 0161 1895537

Carlo Rosa, CEO DiaSorin

"The pandemic generated by the coronavirus outbreak is pushing us to give a strong and effective response to different needs. 
Our molecular diagnostic test is accelerating the testing process in the hospitals, allowing a fast and accurate triage of the patients and lowering the intense pressure that laboratories need to face to detect the new strain of the virus. 
The IgG test we are now developing will contribute to identify people who have developed an immune response to the virus and that, consequently, can safely return to normal life standards."


Video

INTERVIEW WITH CARLO ROSA, DIASORIN GROUP CEO

Quarto Grado, Rete 4


INTERVIEW WITH CARLO ROSA, CEO OF DIASORIN GROUP

DiaSorin's response to COVID-19

CNBC Class, 19 March 2020

THE TRUMP ADMINISTRATION AWARDS DIASORIN TO DEVELOP RAPID COVID-19 TESTS FOR THE NEW CORONAVIRUS WITHIN ONE HOUR

A RAPID RESPONSE MOLECULAR DIAGNOSTIC TEST FOR THE CURRENT NOVEL CORONAVIRUS (COVID-19)

Diasorin Group has officially announced it has completed the studies for the launch of a newly effective molecular diagnostic test for COVID-19, that has been developed by the DiaSorin Research Center in Gerenzano, near Milan.